arrow_back Civic Audit
Share share

Improved Access to Innovative Drugs in Medicaid Program

This act aims to facilitate access to modern, often life-saving drugs within the Medicaid program. It introduces new payment rules that allow for drug billing based on their effectiveness, potentially reducing costs for the healthcare system and patients. This will make innovative therapies, such as gene therapies, more accessible to Medicaid beneficiaries.
Key points
Introduction of value-based payments for drugs in Medicaid, linking costs to actual effectiveness, potentially lowering treatment expenses.
Increased access to innovative therapies, including gene therapies, for patients covered by the Medicaid program.
Requirement for reporting drug prices under new payment systems, enhancing transparency and oversight of expenditures.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 117_HR_7389
Sponsor: Rep. Schrader, Kurt [D-OR-5]
Process start date: 2022-04-04